AUTHOR INDEX

Alderton, P. 61
Arbuthnott, G. W. 281

Barry, M. 71
Biggio, G. 121
Board, P. 357
Butcher, S. P. 281

Cheng, Y. C. 381
Coggan, M. 357
Concas, A. 121
Corda, M. C. 121

Daher, G. C. 189
Diasio, R. B. 189
Dusting, G. J. 323

Edwards, G. 237

Fairbrother, I. S. 281
Feely, J. 71

Giorgi, O. 121
Goldie, R. G. 295
Grant, S. 29
Green, M. D. 61
Gross, J. 61

Hamilton, T. C. 19
Harris, B. E. 189
Herrlich, P. 157
Hintze, T. H. 417
Hufford, C. D. 345
Hyde, J. E. 45

Johnston, P. 357

Kalix, P. 397

Lee, I.-S. 345
Lulich, K. M. 295

MacDonald, P. S. 323
Mebs, D. 223
Muggia, F. M. 61

O'Dwyer, P. J. 371
Oritz de Montellano, P. R. 95
Ownby, C. L. 223
Ozols, R. F. 19

Parker, W. B. 381
Paterson, J. W. 295
Perez, R. P. 19
Putney, J. W. Jr. 427

Rádl, S. 1
Rahmsdorf, H. J. 157
Ross, V. 357
Roth, R. A. 143

Sanna, E. 121
Serra, M. 121
Speyer, J. L. 61
Suzuki, T. 357

Vinegar, A. 143

Webb, G. 357
Weston, A. H. 237
Winquist, R. J. 417
Wintersberger, U. 259

SUBJECT INDEX

A-62824 6
A-65485 9
Acetylcholine receptor-gated K-channel 239
Adenosine-3′,5′-monophosphate
  gated K-channel 240
  vascular effect of prostacyclin 332
Ca^{2+}-Adenosine triphosphatase, in muscle, effect of myotoxin a 231
Adenosine triphosphate-dependent K-channels 240, 242
Adenylate cyclase
  activation by prostacyclin 332
  airway smooth muscle relaxation 297
Adenylate cyclase/β-adrenoceptor system, asthma 302
α-Adrenoceptors
  asthma 308
  in vitro studies of airways 309
  mechanisms of action 307
  subclassification 306
α-Adrenoceptor agonists 306
  effect on airway smooth muscle *in vitro* 309
  effect on asthma 308
α-Adrenoceptor antagonists 306
  effect on airway smooth muscle *in vitro* 309
  effect on asthma 308
α_1-Adrenoceptor-gated K-channel 239
β-Adrenoceptors
  aging and function 330
  airway smooth muscle 299
  density and distribution in lung 298
  molecular nature 297
  respiratory virus interaction 301
  subclassification 296, 299
β-Adrenoceptor agonists
  action on airway smooth muscle 299
  clinical action in lung 304
  role in inflammation 306
  sites of action 305
  tolerance 306
β-Adrenoceptor kinase 297
Adriamycin, resistance in ovarian cancer cells 19
Aging, pulmonary β-adrenoceptor function 300
Airway epithelium, β-adrenoceptor function 301
Airway smooth muscle
  α-adrenoceptors 306
  β-adrenoceptors 299
  clinical action of β-agonists 304
β-Alanine synthase, pyrimidine catabolism 193
Alkylating agents, resistant ovarian cancer cells 19
4-Alkyl-1,4-dihydropyridines, reaction with heme 104
Alkylhydrazines, reaction with heme 103, 106
Allergens, induced reduction in β-adrenergic function on asthmatic lymphocytes 302
Allopurinol, effect on drug metabolism 87
Alpidem
  effect on GABA binding in brain 125
  effect on TBPS binding in brain 126
Alveolar hypoxia 151
Amifloxacin 4
Amiloride, ANF interaction 418
Amines, accumulation in lung 146
Aminopyrine breath test 75
Amiodarone
  accumulation in lung 146
  inhibition of drug metabolism 85, 86
Amphetamine
  comparison with khat alkaloids 397, 401, 402
  induced dopamine release 282, 283
Analgesic drugs, inhibition of drug metabolism 86
Angina pectoris, effect of potassium channel openers 249
Anthracycline, selective alteration of activity by ICRF-187 61–69
Antiarrhythmics, inhibition of drug metabolism 85
Antibacterial agents, DNA gyrase inhibitors 1–17
Antifolate drugs
  malaria chemotherapy 45
  malaria parasite resistance 47
Anti-inflammatory drugs, inhibition of drug metabolism 86
Antipyrine, assessment of enzyme induction and inhibition 74
Antiviral drugs, retroviral RNases H as targets 266
Anxiety, GABAergic transmission 122
Anxiogenic drugs
  Cl^- flux 125, 128
  dopaminergic transmission 135
  GABAergic transmission 124, 124
  TBPS binding 126, 130
Anxiolytic drugs
  Cl^- flux 125, 128
  dopaminergic transmission 135
  GABAergic transmission 122, 124
  TBPS binding 126, 130
AP-1
  binding to TREs 168
  role in tumor promotion 175
AP-2 171
Aphidicolin, effect on drug resistance 24
Aplysiatoxin 158
Appetite suppressant, cathine 405
1-β-D-Arabinofuranosylcytosine
  biochemical modulation
    deaminase inhibitors 36
    growth factors 38
    inhibitors of *de novo* pyrimidine biosynthesis 32
    protective agents 38
    transport blockers 37
  chemistry 204
  cytotoxicity 30
  metabolic sites of action 210
  metabolism 30, 206
  transport 31
  uptake into cells 205
9-β-D-Arabinofuranosyl-2-fluoroadenine, modulation of ara-C 35

Arachidonic acid
phorbol ester induced release 172
potassium channel opening properties 251
prostacyclin biosynthesis 324
Arteannuin B 352
Artelinic acid, metabolism 351
Artemether 347
metabolism 350
Artemisinin 345
metabolism 349
Artesunic acid, metabolism 351
Artheether 346
metabolism 350
Arylhydrazines, reaction with heme 106
Aspartate carbamyl transferase, inhibition by PALA 371, 373
Asthma, role of adrenoceptors 296, 302, 308
effect of α-agonists 308
effect of β-agonists 299, 304
effect of α-antagonists 308
exercise-induced 309
respiratory virus – β-adrenoceptor interaction 301
AT-4140 8
Atherosclerosis, prostacyclin production 333
Atrial natriuretic factor 417
receptors 420
vascular effects *in vitro* 418
vascular effects *in vivo* 421
Atriopeptin I 420, 421
Autoreceptor, control of dopamine release 290
Aversion, cathinone 406
Azacytidine
chemistry 211
metabolic sites of action 213
metabolism 211
uptake into cells 211
Azide, reaction with heme 103

Behavioural effects of khat alkaloids 404
Bendrofluazide 335
Benzodiazepine receptor ligands 124
Benzodiazepines
anxiolytic effect and activation of $GABA_A$ receptor 122
effect on Cl^- flux 126
effect on dopaminergic transmission 135
effect on GABA binding in brain 124
effect on TBPS binding in brain 126
tolerance 132
Benzopyrans, K-channel openers 240
Benzo(a)pyrene, metabolic clearance 147
Benzo(a)pyrene hydroxylase, in lung 146
Bilirubin, in plasma, indicator of enzyme induction 77
Biliverdin formation 110
β-Blockers, inhibition of drug metabolism 85
Blood flow
coronary, effect of ANF 422
kidney, effect of ANF 422
effect of prostacyclin 329
splanchnic, effect of ANF 422
Blood pressure, effect of potassium channel openers 246, 248
Blood vessels
prostacyclin biosynthesis 325
prostacyclin–EDRF interaction 332
BMY-40062 5, 9
Bothropstoxin 234
Brain microdialysis, dopamine release and metabolism *in vivo* 281–293
$BrCCl_3$, reaction with heme 97
Breast cancer, PALA/5-fluorouracil treatment 376
Breath test analysis, assessment of drug metabolism 75
BRL 38226 241
Bronchial hyperactivity, β-adrenoceptor agonists 306
Bronchoconstriction, effect of β-adrenoceptor agonists 299
Bronchodilation, effect of β-adrenoceptor agonists 304
Bryostatin-1, modulation of ara-C 39
Buthionine sulfoximine, effect on chemoresistance 21
t-Butylbicyclophosphorothionate, binding in brain
effect of anxiolytic, anxiogenic drugs 126
effect of stress 130

Cadeguomycin, modulation of ara-C 35
Calcitonin gene-related peptide, vasorelaxant properties 251
Calcium
effect of potassium channel openers on intracellular stores 246
receptor-regulated entry 427–434
capacitative model 429, 431
$Ins(1,4,5)P_3$ 428, 432
route 430
Calcium antagonists, inhibition of drug metabolism 85
Captopril 335
Carbamazepine
erythromycin interaction 86
induction of drug metabolizing enzymes 79
verapamil interaction 85
β-Carbolines
effect on Cl^- flux 126
effect on $GABA_A$/benzodiazepine receptor function 132
effect on GABA binding in brain 124
effect on GABA transmission 123
effect on TBPS binding in brain 127
Cardiovascular drugs, inhibition of drug metabolism 85
Cardiovascular system
effects of khat 399, 402
effect of prostacyclin 329
Cathine 401
behavioural and CNS effects 404
cellular effects 408
somatic effects 402
Cathinone 402
behavioural and CNS effects 404
cellular effects 407
somatic effects 403
Caudoxin 225
Cerebral vasospasm
effect of potassium channel openers 249
effect of prostacyclin 336
Chemotherapeutic agents, inhibition of drug metabolism 86
Chemotherapy, resistance to alkylating agents and cisplatin 19
Chlorgyline, effect on dopamine release 288
Chlorobiocin 2
Chlorpromazine, inhibition of drug metabolism 87

Chronic occlusive arterial disease, effect of potassium channel openers 249
Cigarette smoking
induction of drug metabolizing enzymes 79
effect on prostaglandin production 335
Cimetidine, inhibition of drug metabolism 84
Cinoxacin 3, 4, 6
Ciprofloxacin 4, 5, 7
Cisplatin, resistance in ovarian cancer cells 19
CL 218872
effect on GABA binding in brain 124
effect on TBPS binding in brain 126
Cl^- flux
anxiolytic, anxiogenic drugs 125
stress 128
Clonidine, effect on airway function 306, 312
Collagenase TRE 164
Colorectal cancer, PALA/5-fluorouracil therapy 375
Coronary blood flow, effect of ANF 422
Corticosteroids, interaction with enzyme inducing agents 81
Coumarin antibiotics 1
structure–activity relationships 2
Coumermycin Al 2
Crigler–Najjar syndrome type II 80
Cromakalim
effect on blood pressure 248
interaction with K-channels 242, 244
in vitro pharmacodynamics 245
in vivo pharmacodynamics 246
Crotamine 224
effect on skeletal muscle 231
Crotoxin 225
effect on skeletal muscle 232
Cruoralbin 96
Cyanide, reaction with heme 96
Cyanoguanidines, potassium channel openers 241
^{125}I-Cyanopindolol, binding to pulmonary β-adrenoceptors 3–2
Cyclo-oxygenase, hypertension 334
Cyclopropanone hydrate, reaction with heme 101
Cytidine deaminase
ara-C metabolism 31, 206
azacytidine metabolism 212
fluoropyrimidine metabolism 382
inhibitors and modulation of ara-C 36
Cytochrome P450
N-alkyl adducts 107
covalent binding of prosthetic heme group 109
enzyme induction and inhibition 73
isoenzymes in lung 144
Cytochrome P450 monooxygenases, in lung 144
Cytokines, stimulation of prostacyclin production 327
Cytoprotection, prostacyclin 331

Danfloxacin 9
3-Deazauridine, modulation of ara-C 32
Defibrotide, effect on prostacyclin release 328
Deoxyadenosine, modulation of ara-C 34
Deoxycytidine, ara-C interaction 38
Deoxycytidine kinase, ara-C anabolism 208
Deoxycytidylate deaminase
ara-C catabolism 31, 207
inhibitors and modulation of ara-C 36
Deoxycytidylate kinase
ara-C anabolism 209
azacytidine metabolism 213
5′-Deoxy-5-fluorouridine 204
Deoxyguanosine, modulation of ara-C 34
Deoxytetrahydrouridine, ara-C interaction 36
Deoxyuridine nucleotides, metabolism 389
Dextropropoxyphene, inhibition of drug metabolism 86
Diabetes, prostacyclin production 335
2,2-Dialkyl-1,2-dihydroquinolines, reaction with heme 104
Diazoxide 242, 243
antihypertensive effects 248
interaction with K-channels 244
Diet, effect on drug metabolism 80
Diethylpropion 410
Difloxacin 5
Dihydroalprenolol, binding to pulmonary β-adrenoceptors 298, 302
Dihydroartemisinin 347, 353
Dihydroergocryptine, binding in lung 309
Dihydrofolate reductase, in *Plasmodium* 47
Dihydrofolate reductase mRNA, effect of 5-fluorouracil 384
Dihydrofolate reductase – thymidylate synthetase gene
chromosomal mapping 50
cloning 48
drug resistance in malaria parasites 45–59
point mutations in DHFR-encoding domain 51
Dihydropyrimidinase, pyrimidine catabolism 193
Dihydropyrimidine dehydrogenase, pyrimidine catabolism 192
Diltiazem, inhibition of drug metabolism 85
Dipyridamole, modulation of ara-C 37
Disulfiram, effect on drug metabolism 87
DNA
effect of ara-C on biosynthesis and repair 210
5-fluorouracil action on 387
5-fluorouracil incorporation 203, 388
retroviral, functions of RNases H 264
RNases H 272
role in chemoresistance 22
TPA responsive elements 164
DNA gyrase inhibitors, structure–activity relationships 1–17
DNA primase, 5-fluorouracil interaction 387
DOPAC, neuronal source 288
Dopamine
actions of 290
autoreceptors 290
carrier-dependent release 283
exocytotic release 281
experimental model of release mechanisms 286
intraterminal stores 285
effect of MAO inhibitors 288
receptors 289, 290, 291
releasing agents 282
Dopaminergic transmission, mesocortical pathway 134
anatomical aspects 134
biochemical indexes 134
role of GABAergic transmission in control of neurons 135
stress and function of 135
Doxorubicin, cardiotoxicity, effect of ICRF-187 62
Drug metabolism, enzyme induction and inhibition 71–94
Drug resistance
malaria parasites 45–59
ovarian cancer cells 19
Dyad symmetry elements binding complex 170

Eicosanoids, biosynthesis and metabolism 324
Eicosapentaenoic acid, effect on prostacyclin activity 328
EMD 52692 241
in vivo pharmacodynamics 247
Emotional states, cortical GABAergic and dopaminergic transmission 121
Endothelium-derived hyperpolarizing factor, vascular relaxation 250
Endothelium-derived relaxant factor 249, 250
effect of fish oils on generation of 329
effect on prostacyclin biosynthesis 328
prostacyclin interaction 332
Endothelium, vascular
ANF receptors 420
antithrombotic function 332
prostacyclin production 325
Enoxacin 4, 7
Enzyme induction 71, 73
assessment 74
implications 80
inducers 77
induction of extrahepatic drug metabolizing enzymes 82
Enzyme inhibition 83
anti-inflammatory and analgesic drugs 86
assessment 74
cardiovascular drugs 85
chemotherapeutic agents 86
neuroleptics 87
oral contraceptives 87
ulcer healing drugs 84
Epilepsy, treatment with enzyme inducers 80
Epithelium, airway, β-adrenoceptor function 301
Erythromycin, inhibition of drug metabolism 86
Escherichia coli
reverse transcriptases 269
RNases H 267
Ethanol
induction of drug metabolizing enzymes 79
effect on TBPS binding in brain 128
Ethylhydrazine, reaction with heme 103
Exercise-induced asthma 309

Fear, cortical GABAergic and dopaminergic transmission 121
Fenoterol, bronchodilator effect 300, 304
FG 7142
inhibition of GABAergic system in CNS 133
proconflict response 123
effect on TBPS binding in brain 132
Fish oils, effect on prostacyclin activity 328
Flavin monooxygenases in lung 145
Fleroxacin 4
Flumequine 3, 4
5-Fluorodeoxycytidine 382
5-Fluoro-2′-deoxyuridine
metabolic site of action 202
metabolism 194
uptake into cells 191
5-Fluoro-2′-deoxyuridine monophosphate 200
5,10-methylene tetrahydrofolate and TMP synthetase interaction 387
Fluoropyrimidines
DNA-directed actions 387
metabolism 381, 383
effect on PALA antitumour activity 375
RNA-directed actions 384
structure 382
Fluoroquinolones 5, 7
5-Fluorouracil
chemistry 190
DNA-directed actions 387
metabolic site of action 202
metabolism 191, 381
modulation of ara-C 36
PALA interaction 374
RNA and DNA incorporation 202
RNA-directed action 384
uptake into cells 190
Folate, metabolism in malaria parasites 46
Food intake, effect of khat alkaloids 405
Free radicals, modification of prosthetic heme groups 95–120
Ftorafur 204

GABA, binding in brain
effect of anxiolytic, anxiogenic drugs 124
effect of stress 128
$GABA_A$/benzodiazepine ligands, anxiety 122
$GABA_A$/benzodiazepine receptor
anxiolytic, anxiogenic drugs and Cl^- flux 125
anxiolytic, anxiogenic drugs and GABA binding 124
anxiolytic, anxiogenic drugs and TBPS binding 126
chronic anxiogenic β-carbolines and function of 132
stress and function 121, 128
GABAergic transmission 122
anxiolytic, anxiogenic drugs 124
$GABA_A$/benzodiazepine receptor function and β-carbolines 132
$GABA_A$/benzodiazepine receptor function and stress 128
$GABA_A$/benzodiazepine receptor ligands and anxiety 122
role in control of activity of mesocortical dopaminergic neurons 135
Gene expression, regulation by tumor promoters 157–188
Gilbert's syndrome 80
Glibenclamide 244, 245
D-Glucaric acid, urinary, indicator of enzyme induction 76
Glucocorticoids, interference with transcription factor activity 175
Glucose, effect of enzyme inducers on metabolism 81
γ-Glutamyltransferase, indicator of enzyme induction 76
Glutathione
in heart, effect of doxorubicin 64
role in resistance to alkylating agents and platinum compounds 21
Glutathione *S*-transferases
genetic heterogeneity 357
alpha class 359
mu class 361
pi class 365
role in drug resistance 22
G proteins
α-adrenoceptor action 307
β-adrenoceptor action 297
Green hemoglobins 96
Growth factors, modulation of ara-C 38
Guanosine-3′,5′-monophosphate, vascular, effect of ANF 418

Halocarbons, reaction with heme 97, 108
Heart
  effect of ANF on blood flow 422
  effect of ICRF-187 on anthracycline toxicity 62
  prostacyclin biosynthesis 326
  prostacyclin effects 329
Heme oxygenase 110
Heme prosthetic groups, modification 95
  covalent protein binding 109
  hydrogen abstraction 104
  intrinsic radical reactivity 112
  iron and pyrrole nitrogen addition 104
  meso addition 100
  ring oxidation and degradation 110
  vinyl group addition 96
Hepatitis B viruses, reverse transcriptases 264
High density lipoprotein, effect of enzyme inducers 82
H2TF1 171
Human immunodeficiency virus, reverse transcriptase 263, 267
Hybrid arrest translation, RNase H 273
Hydrogen abstraction, modification of heme prosthetic groups 104
Hydrogen peroxide, reaction with heme 96
Hydrogen sulfide, reaction with heme 99
6β-Hydroxycortisol, urinary excretion, indicator of enzyme induction 76
Hydroxyurea, modulation of ara-C 34
Hypertension
  effect of potassium channel openers 248
  prostacyclin production 334
Hyperthermia, khat-induced 400, 404
Hypotension, ANF-induced 421

ICRF-187, selective alteration of anthracycline activity 61–69
Iloprost 250
  cytoprotective actions 331
Imipramine, accumulation in lung 146
Inflammation, β-adrenoceptor agonists 306
Influenza viruses, β-adrenoceptor interaction 301
Inositol trisphosphate
  calcium entry 428, 431
  gated K-channel 240
Ion exchange, effect of phorbol esters 173
Ion-gated K-channels 239
Ion transport, effect of myotoxic components of snake venom 231
Irloxacin 8
Iron, modification of heme prosthetic groups 104, 114
Ischaemic heart disease, effect of potassium channel openers 249
Ischaemic tissue damage, effect of prostacyclin 336
Isoniazid
  inhibition of drug metabolism 86
  effect of proconflict effect of β-carbolines 123
  stress and convulsant activity 131
  effect on TBPS binding in brain 127
Isoprenaline, bronchodilator action 304

KB-5246 6
Khat 397
  active constituents 401
  behavioural effects 404
  cellular effects 407
  CNS stimulation 398, 404
  peripheral actions 399
  psychosis 398
  somatic effects of alkaloids 402
Kidney, ANF-induced vasodilation 421, 422

Lemakalin 240
Leukemia, biochemical modulation of ara-C 29
Ligand-gated K-channels 239
Lomefloxacin 8
Lung
  accumulation of xenobiotic agents 145
  α-adrenoceptors 308, 309
  β-adrenoceptors 298
  altered physiology and metabolic clearance of xenobiotic agents 151
  cytochrome P450 monooxygenases 144
  determinants of metabolic clearance of xenobiotic agents 145
  flavin monooxygenases 145
  physiologically-based pharmacokinetic modeling: benzo(a)pyrene clearance 147
LY 222675 241

Malaria
  antifolate drugs in chemotherapy 45
  metabolism of sesquiterpene lactones 345–355
  parasite resistance to antifolates 47, 52
Melphalan, resistance in ovarian cancer cells 19
Meso addition, modification of heme prosthetic groups 101
Mesocortical dopaminergic pathway 134
  GABA transmission in control of neurons 135
  stress and function of 135
Metallothioneins, role in cisplatin resistance 22
Metallothionein IIA promoter 166
Methotrexate, modulation of ara-C 35
Methoxamine, effect on asthma 308, 309
5,10-Methylene tetrahydrofolate, FdUMP and TMP synthetase interaction 387
α-Methyl-*p*-tyrosine, effect on dopamine release 285
Metmyoglobin, vinyl modification 97
Mezerin 158
Microcirculation, effect of prostacyclin 330
Miloxacin 3, 4
Minoxidil sulfate 242, 243
  antihypertensive effect 248
Mojave toxin 225
Molsidomine 333
Monoamine oxidase inhibitors
  effect on dopamine release 288
  effect on drug metabolism 87
Murine leukemia virus, reverse transcriptase 261
Muscle, toxic components from snake venom 223, 226
Myocardial ischaemia, effect of potassium channel openers 249
Myoglobin
  covalent binding of prosthetic heme group 109
  nitrite–heme reaction 97
Myotoxic components of snake venom
  peptides 224, 228
  phospholipases A2 225, 232
Myotoxin a 224
  effect on skeletal muscle 228

NAD-441A 11
Nalidixic acid 3

Neuroleptics, inhibition of drug metabolism 87
Neutrophils, effect of prostacyclin 330
NF_kB 171, 172
Nicorandil 241, 243
  hemodynamic effects 247, 249
Nicotinyl alcohol, effect on prostacyclin release 328
Niguldipine 242, 243
Nitric oxide, prostacyclin interaction 332
Nitrite, reaction with heme 97
Nitroglycerin
  prostacyclin interaction 333, 335
  effect on prostacyclin release 328
Nitromethane, reaction with heme 101
Nitroprusside
  prostacyclin interaction 333, 335
  effect on prostacyclin release 328
Nomifensine, effect on dopamine release 284, 285
Norfloxacin 4, 7
Notechis II-5 225
Notexin 225
  effect on skeletal muscle 232, 234
Novobiocin 2
Nucleoside diphosphate kinase
  ara-C metabolism 210
  azacytidine metabolism 213
  fluoropyrimidine metabolism 198
Nucleoside monophosphate kinase, fluoropyrimidine metabolism 198
Nutrition, effect on drug metabolism 80

Ofloxacin 4, 5, 10
Olefins, reaction with heme 107
Oligodeoxyribonucleotides
  antiviral activity 267
  directed RNA cleavage 273
Omeprazole, inhibition of drug metabolizing enzymes 85
Oncogenes, effect of tumor promoters 159
OP-2505 and OP-41483, cytoprotective effect 331
Oral contraceptives, effect on drug metabolism 87
Orotate phosphoribosyltransferase 196
Ouabain, induced dopamine release 282, 284
Ovarian cancer cells, resistance to alkylating agents and cisplatin 19–27
Oxolinic acid 3, 4

Palytoxin 158
Parenchyma, β-adrenoceptors 298
Pargyline, effect on dopamine release 288
PD-124816 7
Pefloxacin 4
Peripheral vascular disease, prostacyclin 336
Phenobarbitone
  effect on Crigler–Najjar syndrome and Gilbert's syndrome 80
  drug interactions 78, 79
  enzyme induction 73, 78
Phentolamine, effect on asthma 308
Phenylbutazone, inhibition of drug metabolism 86
Phenylephrine 306
  effect on lung 308, 312
Phenylhydrazine, reaction with heme 102
Phenytoin
  induction of drug metabolizing enzymes 78
  isoniazid interaction 86
Phorbol esters
  action on genes 159
  activation of transcription factors 168
  induced signal transduction 172
Phospholipase A2
  effect on pulmonary β-adrenoceptor function 303
  snake venoms, myotoxicity 225, 232
Phospholipidosis, pulmonary 146
Phosphonacetyl-L-aspartate
  biochemical modulation of 5-fluorouracil 374
  clinical studies 374
  mechanism of action 371
  modulation of ara-C 32
  pharmacodynamics 373
  pharmacokinetics 372
  preclinical antitumor activity 372
Physiologically-based pharmacokinetic modeling, metabolic clearance of benzo(a)pyrene 147
Pinacidil 241
  antihypertensive effects 248
  interaction with K-channels 244
  in vivo pharmacokinetics 246
Pipemidic acid 3, 4
Piromidic acid 3, 4
Plasminogen activators, effect on prostacyclin release 328
Plasmodium chabaudi, experimentally induced mutations 55
Plasmodium falciparum
  dihydrofolate reductase activity 47
  dihydrofolate reductase–thymidylate synthetase gene 45, 48
  experimentally induced mutations 54
  resistance to antifolates 47
Platelet activating factor
  effect on pulmonary β-adrenoceptors 304
  regulation of prostacyclin biosynthesis 327
Platelets
  prostacyclin actions 330
  prostacyclin–EDRF interaction 332
Platinum compounds, resistance to 19
Polymorphonuclear leukocytes, effect of prostacyclin 330
Polypharmacy, enzyme induction and inhibition 72
Potassium, induced dopamine release 282
Potassium channel openers
  endogenous 250
  synthetic 240
    chemical structures 240
    clinical uses 247
    interactions with specific K-channels 242
    in vitro pharmacodynamics 245
    in vivo pharmacodynamics 246
Potassium channels
  ion-gated 239
  ligand-gated 239
  second-messenger/intracellular metabolite-gated 240
  vascular tone 238
  voltage-gated 238
Prazosin 306
  binding in lung 309
  effect on exercise-induced asthma 309
Pregnancy, prostacyclin production 335
Proguanil 45, 46
Propranolol, inhibition of drug metabolism 85
Prostacyclin
  action in cardiovascular system 329
  action on platelets, blood cells and cytoprotection 330
  activation of adenylate cyclase 332

biosynthesis and metabolism 324
clinical applications 335
interaction with endothelial factors and nitrovasodilator drugs 332
K-channel opening properties 250
production in vascular disease 333
receptors 331
regulation of biosynthesis 326
Prostaglandin E2, modulation of ara-C 38
Protein, phorbol ester induced phosphorylation 173
Protein kinase C
receptor for tumor promoting phorbol esters 172
regulation of prostacyclin biosynthesis 327
Pseudoheme 96
Pulmonary hypertension, effect of prostacyclin 336
Pyrazofuran, modulation of ara-C 32
Pyrazoloimidazole, modulation of ara-C 35
Pyrimethamine 45, 46
Pyrimidine analogues, metabolism 189–222
Pyridimines, inhibition of synthesis by PALA 371, 375
Pyrrole nitrogen, modification of heme prosthetic groups 104

Quinidine, inhibition of drug metabolism 85
Quinolones 1
chiral 10
effect on drug metabolism 86
structure–activity relationships 3

Reserpine, effect on dopamine release 285
Respiratory viruses, interaction with β-adrenoceptors 301
Retroviruses, RNases H 261
Reverse transcriptase 259
avian, murine and simian retroviruses 261
bacterial 269
hepatitis B viruses 264
HIV 263
Rhinovirus-16, β-adrenoceptor interaction 301
Ribonuclease H 260
cellular origin 267
biological functions 272
E.coli 267
multicellular organisms 271
yeast 270
retroviral origin 261
targets for antiviral drugs 266
tool in molecular biology 272
Ribonucleotide reductase, fluoropyrimidine metabolism 199
Ribonucleotide reductase inhibitors, modulation of ara-C 33
Rifampicin, induction of drug metabolizing enzymes 77
RNA
fluorouracil incorporation 202, 384, 385
phorbol ester induced accumulation or decrease 163
fluorouracil incorporation 202, 384, 385
phorbol ester induced accumulation or decrease 163
Ro 15-1788 123
Ro 15-4513 123
Ro 23-9424 11
Ro 31-6930 241
Rosoxacin 3, 4
Rotor's Syndrome 361
RP 49356 241
interaction with K-channels 243, 244
RP 52891 241
Rufloxacin 5, 6

Salbutamol, bronchodilator effect 300, 302, 304
Sarcoma-leukosis virus group, reverse transcriptase from 261
Sarcoplasmic reticulum, effect of myotoxin a 231
Satellite cells, effect of myotoxic phospholipases A2 232
SDZ PCO 400, effect on vascular tone 247
Serum response factor p 67 170
Sesquiterpene lactone antimalarials, metabolism 345–355
Signal transduction, phorbol ester induced 172
Simian retroviruses, reverse transcriptase from 263
Skeletal muscle
effect of ANF on circulation 423
normal structure 226
snake venom induced necrosis 223, 228
Skin tumor promoters 158
Smoking, drug interactions 79
Snake venoms 223
myotoxic peptides 224
myotoxic phospholipases A2 225
pathogenesis of myonecrosis 226
SO 121 241
Sodium channel, effect of myotoxins 231
Sodium–potassium–chloride transport system, effect of phorbol esters 173
Species differences, ANF-induced vasodilation 420
Splanchnic circulation, effect of ANF 423
Stomatitis, khat induced 400
Streptokinase, effect on prostacyclin release 328
Stress
function of mesocortical dopaminergic pathway 135
$GABA_A$/benzodiazepine receptor function 128
GABAergic transmission 122
Subarachnoid hemorrhage, effect of prostacyclin 336
Sulfhemoglobin 99
Sulfinpyrazine, inhibition of drug metabolism 86
Sulfite, reaction with heme 104
Sulfonamides, effect on drug metabolism 86
SV 40 promoter 166
protein binding 170
Sydnones, reaction with heme 107
Systemic lupus erythromatosis, prostacyclin production 335

Taipoxin, effect on skeletal muscle 232
Teleocidin 158
Temefloxacin 8
Terbutaline, bronchodilator action 304
12-*O*-Tetradecanoylphorbol-13-acetate 158
induced signal transduction 172
responsive DNA elements 164
protein binding 167
responsive genes 160–162
RNA accumulation or decrease 163
Tetrahydrouridine 207, 212
ara-C interaction 36
Tetramic acid analogues 11
Thapsigargin 431

Thioformamide derivatives, potassium channel openers 241
Thioridazine, inhibition of drug metabolism 87
Thrombotic thrombocytopeanic purpura, prostacyclin production 335
Thromboxane A2, production by vascular tissues 325
Thymidine, ara-C interaction 33
Thymidine kinase 197
Thymidine nucleotides, metabolism 389
Thymidine phosphorylase 196
Thymidylate synthase, fluoropyrimidine interaction 200, 387
Thymus, RNases H in 271
Thyroid, effect of enzyme inducers on metabolism 81
TK-1000, cytoprotective effect 331
Tosufloxacin 8
Trachea
  α-adrenoceptors 310
  β-adrenoceptors 298
Transplant preservation, effect of prostacyclin 336
TREs 164
  protein binding 167
Triacetyloleandomycin, inhibition of drug metabolism 86
Tumor promoters, regulation of gene expression 157–188
Tyramine, induced dopamine release 282, 285

Ulcer healing drugs, enzyme inhibition 84
Uracil *N*-glycosylase, 5-fluorouracil toxicity 391
Uridine/cytidine kinase, azacytidine metabolism 212
Uridine kinase 195
Uridine phosphorylase 194

Valproic acid, inhibition of drug metabolism 87
Vascular disease
  clinical applications of prostacyclin 335
  prostacyclin production 333
Vascular smooth muscle
  effect of ANF 418
  potassium channel openers 238, 245, 247, 250
Vascular tissue
  prostacyclin action 329
  prostacyclin biosynthesis 325
Vasodilation, ANF induced 417
  in vitro 418
  in vivo 421
Verapamil, inhibition of oxidative metabolism 85
Veratrine, induced dopamine release 282, 284
Verdoheme 111
Vinyl group addition, heme 96
Viral genes, effect of tumor promoters 161, 163
Virus, interaction with β-adrenoceptors 301
Vitamin D, effect of inducing agents on metabolism 81
Voltage-gated K-channel 238

WAY-120,491 247
WB4101 307

Yeast, RNases H 270

ZK 93423 and ZK 91296
  effect on GABA binding in brain 125
  effect on TBPS binding in brain 126
Zolpidem
  effect on GABA binding in brain 125
  effect on TBPS binding in brain 126